{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T23:07:50Z","timestamp":1770246470650,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10067-025-07840-y","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T21:12:12Z","timestamp":1764105132000},"page":"1117-1128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective analysis of myositis-specific antibody-positive veteran survival between 2011 and 2023"],"prefix":"10.1007","volume":"45","author":[{"given":"Koichi","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siamak","family":"Moghadam-Kia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana P.","family":"Ascherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir M.","family":"Liarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"7","key":"7840_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344\u2013347. https:\/\/doi.org\/10.1056\/NEJM197502132920706","journal-title":"N Engl J Med"},{"issue":"1","key":"7840_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/rir-2022-0001","volume":"3","author":"F Halilu","year":"2022","unstructured":"Halilu F, Christopher-Stine L (2022) Myositis-specific antibodies: overview and clinical utilization. Rheumatol Immunol Res 3(1):1\u201310. https:\/\/doi.org\/10.2478\/rir-2022-0001","journal-title":"Rheumatol Immunol Res"},{"issue":"1","key":"7840_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/jalm\/jfab108","volume":"7","author":"M Basuita","year":"2022","unstructured":"Basuita M, Fidler LM (2022) Myositis antibodies and interstitial lung disease. J Appl Lab Med 7(1):240\u2013258. https:\/\/doi.org\/10.1093\/jalm\/jfab108","journal-title":"J Appl Lab Med"},{"issue":"1","key":"7840_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","volume":"280","author":"Z Betteridge","year":"2016","unstructured":"Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280(1):8\u201323. https:\/\/doi.org\/10.1111\/joim.12451","journal-title":"J Intern Med"},{"issue":"11","key":"7840_CR5","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1007\/s10067-021-05797-2","volume":"40","author":"GN Gomez","year":"2021","unstructured":"Gomez GN, Perez N, Braillard Poccard A et al (2021) Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology. Clin Rheumatol 40(11):4473\u20134483. https:\/\/doi.org\/10.1007\/s10067-021-05797-2","journal-title":"Clin Rheumatol"},{"issue":"11","key":"7840_CR6","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1007\/s10067-022-06291-z","volume":"41","author":"L Wen","year":"2022","unstructured":"Wen L, Chen X, Cheng Q et al (2022) Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China. Clin Rheumatol 41(11):3419\u20133427. https:\/\/doi.org\/10.1007\/s10067-022-06291-z","journal-title":"Clin Rheumatol"},{"issue":"1","key":"7840_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10067-018-4267-z","volume":"38","author":"E Zampeli","year":"2019","unstructured":"Zampeli E, Venetsanopoulou A, Argyropoulou OD et al (2019) Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clin Rheumatol 38(1):125\u2013132. https:\/\/doi.org\/10.1007\/s10067-018-4267-z","journal-title":"Clin Rheumatol"},{"issue":"11","key":"7840_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1001\/jamadermatol.2022.3112","volume":"158","author":"CM Bolender","year":"2022","unstructured":"Bolender CM, Jimenez A, Clarke JT, Willson TM, Stevens VW, Rhoads JLW (2022) Incidence of dermatomyositis in a nationwide cohort study of US veterans. JAMA Dermatol 158(11):1321\u20131323. https:\/\/doi.org\/10.1001\/jamadermatol.2022.3112","journal-title":"JAMA Dermatol"},{"issue":"3","key":"7840_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1258\/ar.2011.110482","volume":"53","author":"TM Aalokken","year":"2012","unstructured":"Aalokken TM, Naalsund A, Mynarek G et al (2012) Diagnostic accuracy of computed tomography and histopathology in the diagnosis of usual interstitial pneumonia. Acta Radiol 53(3):296\u2013302. https:\/\/doi.org\/10.1258\/ar.2011.110482","journal-title":"Acta Radiol"},{"issue":"7","key":"7840_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.rmed.2015.05.008","volume":"109","author":"V Soyseth","year":"2015","unstructured":"Soyseth V, Aalokken TM, Mynarek G et al (2015) Diagnosis of biopsy verified usual interstitial pneumonia by computed tomography. Respir Med 109(7):897\u2013903. https:\/\/doi.org\/10.1016\/j.rmed.2015.05.008","journal-title":"Respir Med"},{"issue":"7","key":"7840_CR11","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/art.30344","volume":"63","author":"O Benveniste","year":"2011","unstructured":"Benveniste O, Drouot L, Jouen F et al (2011) Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 63(7):1961\u20131971. https:\/\/doi.org\/10.1002\/art.30344","journal-title":"Arthritis Rheum"},{"issue":"2","key":"7840_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/acr.20662","volume":"64","author":"AL Mammen","year":"2012","unstructured":"Mammen AL, Pak K, Williams EK et al (2012) Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care & Research 64(2):269\u2013272. https:\/\/doi.org\/10.1002\/acr.20662","journal-title":"Arthritis Care & Research"},{"issue":"5","key":"7840_CR13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/rheumatology\/ker408","volume":"51","author":"Y Muro","year":"2012","unstructured":"Muro Y, Sugiura K, Hoshino K, Akiyama M (2012) Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM\/interstitial lung disease during disease remission. Rheumatology (Oxford) 51(5):800\u2013804. https:\/\/doi.org\/10.1093\/rheumatology\/ker408","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"7840_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101486","volume":"34","author":"H Chinoy","year":"2020","unstructured":"Chinoy H, Lilleker JB (2020) Pitfalls in the diagnosis of myositis. Best Pract Res Clin Rheumatol 34(1):101486. https:\/\/doi.org\/10.1016\/j.berh.2020.101486","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"7840_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/BOR.0000000000001039","volume":"36","author":"FK McMorrow","year":"2024","unstructured":"McMorrow FK, Anwyll N, Tansley SL (2024) Autoantibody testing in myositis: an update. Curr Opin Rheumatol 36(6):481\u2013487. https:\/\/doi.org\/10.1097\/BOR.0000000000001039","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"7840_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101771","volume":"36","author":"S Kardes","year":"2022","unstructured":"Kardes S, Gupta L, Aggarwal R (2022) Cancer and myositis: who, when, and how to screen. Best Pract Res Clin Rheumatol 36(2):101771. https:\/\/doi.org\/10.1016\/j.berh.2022.101771","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"7840_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","volume":"73","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Cassidy E, Fertig N et al (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73(1):227\u2013232. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201800","journal-title":"Ann Rheum Dis"},{"key":"7840_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.872615","volume":"13","author":"N Zhao","year":"2022","unstructured":"Zhao N, Jiang W, Wu H et al (2022) Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease. Front Immunol 13:872615. https:\/\/doi.org\/10.3389\/fimmu.2022.872615","journal-title":"Front Immunol"},{"issue":"9","key":"7840_CR19","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","volume":"34","author":"J Rojas-Serrano","year":"2015","unstructured":"Rojas-Serrano J, Herrera-Bringas D, Mejia M, Rivero H, Mateos-Toledo H, Figueroa JE (2015) Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD). Clin Rheumatol 34(9):1563\u20131569. https:\/\/doi.org\/10.1007\/s10067-015-3023-x","journal-title":"Clin Rheumatol"},{"issue":"2","key":"7840_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","volume":"12","author":"B Hervier","year":"2012","unstructured":"Hervier B, Devilliers H, Stanciu R et al (2012) Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 12(2):210\u2013217. https:\/\/doi.org\/10.1016\/j.autrev.2012.06.006","journal-title":"Autoimmun Rev"},{"issue":"5","key":"7840_CR21","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/bjd.18133","volume":"181","author":"PC Gandiga","year":"2019","unstructured":"Gandiga PC, Zhang J, Sangani S, Thomas P, Werth VP, George MD (2019) Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice. Br J Dermatol 181(5):1090\u20131092. https:\/\/doi.org\/10.1111\/bjd.18133","journal-title":"Br J Dermatol"},{"issue":"5","key":"7840_CR22","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5175","volume":"9","author":"LM Hodgkinson","year":"2021","unstructured":"Hodgkinson LM, Wu TT, Fiorentino DF (2021) Dermatomyositis autoantibodies: how can we maximize utility? Ann Transl Med 9(5):433. https:\/\/doi.org\/10.21037\/atm-20-5175","journal-title":"Ann Transl Med"},{"issue":"8","key":"7840_CR23","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1007\/s10067-021-05658-y","volume":"40","author":"M Maheswaranathan","year":"2021","unstructured":"Maheswaranathan M, Johannemann A, Weiner JJ, Jessee R, Eudy AM, Criscione-Schreiber L (2021) Real world utilization of the myositis autoantibody panel. Clin Rheumatol 40(8):3195\u20133205. https:\/\/doi.org\/10.1007\/s10067-021-05658-y","journal-title":"Clin Rheumatol"},{"key":"7840_CR24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2147\/JMDH.S404017","volume":"16","author":"AT Melo","year":"2023","unstructured":"Melo AT, Dourado E, Campanilho-Marques R et al (2023) Myositis multidisciplinary clinic in a tertiary referral center. J Multidiscip Healthc 16:1127\u20131139. https:\/\/doi.org\/10.2147\/JMDH.S404017","journal-title":"J Multidiscip Healthc"},{"issue":"8","key":"7840_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/art.1780230802","volume":"23","author":"M Nishikai","year":"1980","unstructured":"Nishikai M, Reichlin M (1980) Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 23(8):881\u2013888. https:\/\/doi.org\/10.1002\/art.1780230802","journal-title":"Arthritis Rheum"},{"issue":"12","key":"7840_CR26","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M et al (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 69(12):2271\u20132282. https:\/\/doi.org\/10.1002\/art.40320","journal-title":"Arthritis Rheumatol"},{"key":"7840_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge Z, Tansley S, Shaddick G et al (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48\u201355. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.001","journal-title":"J Autoimmun"},{"issue":"7","key":"7840_CR28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","volume":"68","author":"MG Cruellas","year":"2013","unstructured":"Cruellas MG, Viana Vdos S, Levy-Neto M, Souza FH, Shinjo SK (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics Sao Paulo 68(7):909\u2013914. https:\/\/doi.org\/10.6061\/clinics\/2013(07)04","journal-title":"Clinics Sao Paulo"},{"issue":"12","key":"7840_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.17219\/acem\/141181","volume":"30","author":"A Rams","year":"2021","unstructured":"Rams A, Kosalka-Wegiel J, Kuszmiersz P et al (2021) Characteristics of idiopathic inflammatory myopathies with novel myositis-specific autoantibodies. Adv Clin Exp Med 30(12):1239\u20131248. https:\/\/doi.org\/10.17219\/acem\/141181","journal-title":"Adv Clin Exp Med"},{"issue":"5","key":"7840_CR30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ejim.2013.01.002","volume":"24","author":"I Marie","year":"2013","unstructured":"Marie I, Josse S, Decaux O et al (2013) Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur J Intern Med 24(5):474\u2013479. https:\/\/doi.org\/10.1016\/j.ejim.2013.01.002","journal-title":"Eur J Intern Med"},{"issue":"10","key":"7840_CR31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","volume":"11","author":"I Marie","year":"2012","unstructured":"Marie I, Josse S, Decaux O et al (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11(10):739\u2013745. https:\/\/doi.org\/10.1016\/j.autrev.2012.01.006","journal-title":"Autoimmun Rev"},{"issue":"6","key":"7840_CR32","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/art.21883","volume":"54","author":"Y Yamasaki","year":"2006","unstructured":"Yamasaki Y, Yamada H, Nozaki T et al (2006) Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis\/dermatomyositis. Arthritis Rheum 54(6):2004\u20132009. https:\/\/doi.org\/10.1002\/art.21883","journal-title":"Arthritis Rheum"},{"key":"7840_CR33","doi-asserted-by":"crossref","unstructured":"Flashner BM, J.; Rice, M.B.; Hallowell, R. Anti-Mi-2-associated ILD: A Unique Disease or a Mixed Picture? presented at: A46 DIAGNOSIS AND MONITORING OF ILD; 2024; American Thoracic Society.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1779"},{"issue":"6","key":"7840_CR34","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.jaad.2020.03.058","volume":"83","author":"G Monseau","year":"2020","unstructured":"Monseau G, Landon-Cardinal O, Stenzel W et al (2020) Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy. J Am Acad Dermatol 83(6):1759\u20131763. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.058","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"7840_CR35","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/art.42311","volume":"75","author":"CA Mecoli","year":"2023","unstructured":"Mecoli CA, Igusa T, Chen M et al (2023) Subsets of idiopathic inflammatory myositis enriched for contemporaneous cancer relative to the general population. Arthritis Rheumatol 75(4):620\u2013629. https:\/\/doi.org\/10.1002\/art.42311","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"7840_CR36","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/ard.2006.068502","volume":"66","author":"H Chinoy","year":"2007","unstructured":"Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66(10):1345\u20131349. https:\/\/doi.org\/10.1136\/ard.2006.068502","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7840_CR37","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/rheumatology\/kes073","volume":"51","author":"Y Muro","year":"2012","unstructured":"Muro Y, Ishikawa A, Sugiura K, Akiyama M (2012) Clinical features of anti-TIF1- antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1- or anti-Mi-2 autoantibodies. Rheumatology (Oxford) 51(8):1508\u20131513. https:\/\/doi.org\/10.1093\/rheumatology\/kes073","journal-title":"Rheumatology (Oxford)"},{"key":"7840_CR38","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3750","author":"L Liang","year":"2020","unstructured":"Liang L, Zhang YM, Chen H et al (2020) Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis. Eur J Dermatol. https:\/\/doi.org\/10.1684\/ejd.2020.3750","journal-title":"Eur J Dermatol"},{"issue":"12","key":"7840_CR39","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/1756-185X.14428","volume":"25","author":"X Li","year":"2022","unstructured":"Li X, Zhou Q, Wu P et al (2022) A prognostic analysis of antisynthetase syndrome-related interstitial lung disease. Int J Rheum Dis 25(12):1368\u20131375. https:\/\/doi.org\/10.1111\/1756-185X.14428","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"7840_CR40","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/acr.21895","volume":"65","author":"I Marie","year":"2013","unstructured":"Marie I, Josse S, Hatron PY et al (2013) Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 65(5):800\u2013808. https:\/\/doi.org\/10.1002\/acr.21895","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"7840_CR41","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.nmd.2022.05.011","volume":"32","author":"J Damoiseaux","year":"2022","unstructured":"Damoiseaux J, Mammen AL, Piette Y, Benveniste O, Allenbach Y, Group EtWS (2022) 256th ENMC international workshop: myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021. Neuromuscul Disord 32(7):594\u2013608. https:\/\/doi.org\/10.1016\/j.nmd.2022.05.011","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"7840_CR42","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00296-023-05279-5","volume":"43","author":"J Loarce-Martos","year":"2023","unstructured":"Loarce-Martos J, Calvo Sanz L, Garrote-Corral S et al (2023) Myositis autoantibodies detected by line blot immunoassay: clinical associations and correlation with antibody signal intensity. Rheumatol Int 43(6):1101\u20131109. https:\/\/doi.org\/10.1007\/s00296-023-05279-5","journal-title":"Rheumatol Int"},{"issue":"7","key":"7840_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15261","volume":"27","author":"SB Ali","year":"2024","unstructured":"Ali SB, Hender L, Khoo T, Beroukas D, Griggs K, Limaye V (2024) Anti-synthetase syndrome in South Australia over 13 years: a clinical descriptive study. Int J Rheum Dis 27(7):e15261. https:\/\/doi.org\/10.1111\/1756-185X.15261","journal-title":"Int J Rheum Dis"},{"key":"7840_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-002076","author":"S Nayebirad","year":"2023","unstructured":"Nayebirad S, Mohamadi A, Yousefi-Koma H et al (2023) Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis. BMJ Open Respir Res. https:\/\/doi.org\/10.1136\/bmjresp-2023-002076","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"7840_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-025-00592-5","volume":"12","author":"VM Liarski","year":"2025","unstructured":"Liarski VM (2025) Retrospective analysis of US veterans with inclusion body myositis: initial findings from the Veterans Affairs Corporate Data Warehouse. Mil Med Res 12(1):6. https:\/\/doi.org\/10.1186\/s40779-025-00592-5","journal-title":"Mil Med Res"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07840-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07840-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07840-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:01:51Z","timestamp":1769763711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07840-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7840"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07840-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM-K, DPA, and VML are part-time\u00a0employees of VA Pittsburgh Healthcare System, Pittsburgh, PA. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}